Jakarta, The Indonesia Post – After receiving 15 million bulk doses of Covid-19 vaccine from Sinovac, on January 12, 2021, Bio Farma is ready to continue the production process of these raw materials, at the fill and finish facility in Bio Farma to become the final product. The raw material for the Covid-19 vaccine began production in mid-January 2021.
The President Director of Bio Farma, Honesti Basyir, said that the results of the production process of this raw material will complement the supply of the Covid-19 vaccine, in a three-dose finish product package that was previously received in December 2020. This was said by the President Director of Bio Farma Honesti Basyir, during the DPR Commission IX Working Visit to Bio Farma, on Friday, January 21, 2021.
“Collaboration between Bio Farma and Sinovac, through two mechanisms, namely imports in the form of finished goods / single dose finished products intended for front liners in Indonesia, and imports in the form of bulk / vaccine concentrate. From this bulk, it will be further processed at Bio Farma in the fill and finish facilities in Bio Farma, “said Honesti,
Honesti continued, we received three million doses of the Covid-19 vaccine in the form of finished goods in December 2020. Of these, 1.2 million doses of which have been distributed to 34 provinces, and the remaining 1.8 million doses have started to be distributed in stage 2 this week, to 34 Provinces. As for raw materials, Bio Farma will receive as many as 140 million doses, which will be received in stages. In the first phase, we received 15 million doses of this raw material on January 12, 2021.
“As of today (21/1), there have been 4 million doses that have been produced. The status of these products, currently in the process of quality control, will be sent to the POM to get a lot release so that they can be distributed, and it is estimated that by February 2021, 4 million doses of vaccine will be ready, “said Honesti.
For the distribution of vaccines itself, our group Bio Farma, together with members of PT Kimia Farma, (Tbk) and PT Indofarma (Tbk), already has 48 branches or warehouses throughout Indonesia. We can optimize this, in terms of technology, Bio Farma has prepared an end-to-end digital solution starting from the production plant, distribution process and arriving at the final destination (health facilities). And the distribution process can be monitored in real time at the Command Center of BUMN Pharmacy Holding.
Indonesia itself, needs the Covid-19 vaccine for its 181.5 million people, or the equivalent of 426 million doses. To anticipate the scarcity of Covid-19 vaccine supply from Covid-19 producers, the Indonesian government through the Ministry of Health has issued Permenkes Number HK.01.07 / MENKES / 12758/2020 concerning Determination of Types of Vaccines for Implementation of Coronavirus Disease 2019 (Covid-19) Vaccination. From the Permenkes, the supply of vaccines will be obtained from the production of PT Bio Farma (Persero), AstraZeneca, China National Pharmaceutical Group Corporation (Sinopharm), Moderna, Pfizer Inc. and BioNTech and Sinovac Life Sciences Co., Ltd and Novovax. Of course, the entire Covid-19 vaccine must report the results of Clinical Trials 1 to 3, and obtain EUA from the POM.
To be able to meet the needs of the Covid-19 vaccine needed by Indonesia, Bio Farma has implemented an amendment to the supply agreement signed by Honesti Basyir on December 30, 2021, with Canadian pharmaceutical companies, AstraZeneca, and Novovax, each with 50 million doses. AstraZeneca is expected to receive an Emergency Use Authorization (EUA) from the POM in April 2021
Meanwhile, Novovax will begin to be supplied in Q2 2021 through a member of the Pharmaceutical SOE Holding, Indofarma, which is expected to get an EUA from the POM in May 2021. So that the total that has been secured from the two companies for Indonesia is 100 million doses. Apart from the two companies, Bio Farma will also sign a supply agreement with Pfizer Biontech. (mhn / bbs)
Comment